Slide 1: Managing Director Report 6 Months to 31 Jan 2016
For personal use only Managing Director Report 6 Months to 31 Jan 2016 23 March 2016
Slide 2: Vision and Mission Statement
For personal use only Vision and Mission Statement Vision: To optimise the health and development of adults, infants and children. Mission: To deliver science based bioactives which provide health benefits to adults, infants, children and to the medical food markets.
Slide 3: Half Year Performance Highlights
For personal use only Half Year Performance Highlights 9 Total Revenue up 9 Revenue from new 23.9% driven by customers is 16% improved demand continues positive trend $801K up 9 Net Profit 9 Inventory managed at 12.6% on half year 2015 $13m in line with revenue growth 9 Operating expenses down 2.5%
Slide 4: Half Year 2016 Results
For personal use only Half Year 2016 Results AUD million 4E Reported 4E Reported •23.9% year on year revenue 31 Jan 2016 31 Jan 2015 growth Revenue $19.7 $16.0 •Recovery of traditional Profit before $1.08 $0.91 markets and customers and tax encouraging growth in sales to EBITDA $1.26 $1.14 new custo
Slide 5: Balance Sheet January 2016
For personal use only Balance Sheet 31 January 2016 AUD million Reported Reported Movement 31 Jan 2016 31 July 2015 Cash $7.1 $9.6 2.5 È •Cash balance strong $7.1m Trade $11.1 $5.5 5.6 Ç Receivables •Trade receivables Inventories $13.1 $14.2 1.1 È reflect the increased Total Current $31.4 $29.5 1.9
Slide 6: Sales by geography & product
For personal use only Sales by geography & product • Continued strong presence • Encapsulation technology through Oceania and Asia delivers a differentiated • Investment in New Zealand product which delivers new Dairy and Infant formula is customers providing new opportunities • Encapsulated Powders
Slide 7: An Update on Growth Platforms
For personal use only An Update on Growth Platforms Focus on infant formula customers and market New Development products, of medical process and foods market program development
Slide 8: Growth Platform: Focus on infant formula customers and market
Focus on For personal use only Growth Platform infant formula customers Continued focus on the infant formula market and market ♣ The Chinese infant formula market has seen a recovery with strong sales from Australia and New Zealand ♣ Traditional Nu-Mega customers sales are recovering, reflected in
Slide 9: Growth Platform: Developing new markets
New For personal use only products, Growth Platform process and market Developing new markets development ♣ The first production run at Waikato in New Zealand is complete with production samples distributed to customers for evaluation (customer trials tend to run 6- 12 months) ♣ Waikato provides the
Slide 10: Growth Platform: Development of medical foods program
Development For personal use only Growth Platform of medical foods program Treatment for Premature babies ♣ The phase III clinical trial of Clover's DHA emulsion product for improving respiratory health in premature babies was due to be finalised in December 2015; at the time of reporting, the trial
Slide 11: FY2016 Outlook & Priorities
For personal use only FY2016 Outlook & Priorities • Leverage the two child policy in China, grow sales in the region • Develop new product applications in collaboration with customers • Organic growth with emphasis on Oceania, Asia and Europe • Diversify product portfolio and attract new customers •
Slide 12: Disclaimer
For personal use only Disclaimer The release, publication or distribution of this presentation in certain jurisdictions may be restricted by law and therefore persons in such jurisdictions into which this presentation is released, published or distributed should inform themselves about and observe s